Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis.

ABSTRACT:

Background

Coronary stenting in patients on dialysis has increased by nearly 50% over the past decade, despite heightened risks of associated stent thrombosis and bleeding relative to the general population. We examined clopidogrel, prasugrel or ticlopidine use after percutaneous coronary intervention (PCI) with stenting in patients on dialysis. We conducted 3-, 6-, and 12-month landmark analyses to test the hypothesis that thienopyridine discontinuation prior to those time points would be associated with higher risks of death, myocardial infarction, or repeat revascularization, and a lower risk of major bleeding episodes compared with continued thienopyridine use.

Methods and results

Using the US Renal Data System, we identified 8458 patients on dialysis with Medicare Parts

SUBMITTER: Chang TI 

PROVIDER: S-EPMC4323824 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature